Detalhe da pesquisa
1.
No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.
Antimicrob Agents Chemother
; : e0033424, 2024 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38864613
2.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939812
3.
Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
Antimicrob Agents Chemother
; 66(6): e0013322, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35546110
4.
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
Antimicrob Agents Chemother
; 66(5): e0222321, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491829
5.
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Antimicrob Agents Chemother
; 65(12): e0121621, 2021 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570651
6.
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Liver Int
; 40(5): 1042-1051, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31765046
7.
Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2.
Antimicrob Agents Chemother
; 63(12)2019 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31527040
8.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739366
9.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology
; 67(6): 2113-2126, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29473975
10.
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
Bioorg Med Chem Lett
; 29(5): 700-706, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711390
11.
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
J Gastroenterol Hepatol
; 34(9): 1597-1603, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30779220
12.
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
J Gastroenterol Hepatol
; 34(1): 12-21, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311701
13.
Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
J Biol Chem
; 292(15): 6202-6212, 2017 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28228479
14.
In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30150466
15.
Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.
J Antimicrob Chemother
; 73(1): 109-117, 2018 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29029095
16.
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Liver Int
; 38(9): 1583-1591, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29461687
17.
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
Bioorg Med Chem Lett
; 28(10): 1954-1957, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653894
18.
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
Antimicrob Agents Chemother
; 61(7)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416549
19.
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
J Hepatol
; 65(6): 1112-1119, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27542322
20.
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Antimicrob Agents Chemother
; 60(5): 2954-64, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26926625